GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nxera Pharma Co Ltd (OTCPK:SOLTF) » Definitions » Cyclically Adjusted PS Ratio

Nxera Pharma Co (Nxera Pharma Co) Cyclically Adjusted PS Ratio : 9.10 (As of May. 22, 2024)


View and export this data going back to . Start your Free Trial

What is Nxera Pharma Co Cyclically Adjusted PS Ratio?

As of today (2024-05-22), Nxera Pharma Co's current share price is $8.92. Nxera Pharma Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $0.98. Nxera Pharma Co's Cyclically Adjusted PS Ratio for today is 9.10.

The historical rank and industry rank for Nxera Pharma Co's Cyclically Adjusted PS Ratio or its related term are showing as below:

SOLTF' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 8.6   Med: 17.52   Max: 42.01
Current: 9.48

During the past years, Nxera Pharma Co's highest Cyclically Adjusted PS Ratio was 42.01. The lowest was 8.60. And the median was 17.52.

SOLTF's Cyclically Adjusted PS Ratio is ranked worse than
66.07% of 507 companies
in the Biotechnology industry
Industry Median: 5.55 vs SOLTF: 9.48

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Nxera Pharma Co's adjusted revenue per share data for the three months ended in Mar. 2024 was $0.344. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $0.98 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Nxera Pharma Co Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Nxera Pharma Co's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nxera Pharma Co Cyclically Adjusted PS Ratio Chart

Nxera Pharma Co Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.70 18.65 16.40 15.82 9.50

Nxera Pharma Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.62 10.81 10.61 9.50 10.74

Competitive Comparison of Nxera Pharma Co's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Nxera Pharma Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nxera Pharma Co's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nxera Pharma Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Nxera Pharma Co's Cyclically Adjusted PS Ratio falls into.



Nxera Pharma Co Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Nxera Pharma Co's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=8.92/0.98
=9.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nxera Pharma Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Nxera Pharma Co's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.344/107.2000*107.2000
=0.344

Current CPI (Mar. 2024) = 107.2000.

Nxera Pharma Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.042 98.000 0.046
201409 0.055 98.500 0.060
201412 0.058 97.900 0.064
201503 0.406 97.900 0.445
201506 0.084 98.400 0.092
201509 0.288 98.500 0.313
201512 0.646 98.100 0.706
201603 0.054 97.900 0.059
201606 2.111 98.100 2.307
201609 0.109 98.000 0.119
201612 0.155 98.400 0.169
201703 0.244 98.100 0.267
201706 0.370 98.500 0.403
201709 0.336 98.800 0.365
201712 0.126 99.400 0.136
201803 0.080 99.200 0.086
201806 0.100 99.200 0.108
201809 0.113 99.900 0.121
201812 0.125 99.700 0.134
201903 0.369 99.700 0.397
201906 0.232 99.800 0.249
201909 0.324 100.100 0.347
201912 0.229 100.500 0.244
202003 0.134 100.300 0.143
202006 0.163 99.900 0.175
202009 0.222 99.900 0.238
202012 0.565 99.300 0.610
202103 0.138 99.900 0.148
202106 0.215 99.500 0.232
202109 0.052 100.100 0.056
202112 1.424 100.100 1.525
202203 0.116 101.100 0.123
202206 0.122 101.800 0.128
202209 0.522 103.100 0.543
202212 0.603 104.100 0.621
202303 0.086 104.400 0.088
202306 0.104 105.200 0.106
202309 0.273 106.200 0.276
202312 0.605 106.800 0.607
202403 0.344 107.200 0.344

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Nxera Pharma Co  (OTCPK:SOLTF) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Nxera Pharma Co Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Nxera Pharma Co's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Nxera Pharma Co (Nxera Pharma Co) Business Description

Traded in Other Exchanges
Address
2-1 Kojimachi, Chiyoda-ku, PMO Hanzomon 11th Floor, Tokyo, JPN, 102-0083
Sosei Group Corp is an international biopharmaceutical company that develops treatments for a wide range of illnesses. The company utilizes its peptide platform technologies and nanotechnology to develop its product pipeline. Sosei actively seeks partnerships to aid its product development. The company's strategy for commercializing its therapies include utilizing its subsidiaries' drug discovery technologies, supplying technology to other companies, developing products in-house, and product licensing.

Nxera Pharma Co (Nxera Pharma Co) Headlines

From GuruFocus